Abstract
The triple combination of nizatidine, clarithromycin, and bismuth subcitrate resulted in an ulcer healing rate of 98% and an H. pylori eradication rate of 90%. Corresponding 'intention-to-treat' figures were 92% and 84%, respectively. These results suggest that further studies, shorter in duration, using lower dosages, and possibly testing other combinations with a double-blind methodology, are required.
Publication types
-
Comparative Study
-
Multicenter Study
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Anti-Ulcer Agents / therapeutic use*
-
Clarithromycin / therapeutic use*
-
Drug Therapy, Combination
-
Duodenal Ulcer / drug therapy*
-
Duodenal Ulcer / microbiology*
-
Female
-
Helicobacter pylori / drug effects*
-
Humans
-
Male
-
Middle Aged
-
Nizatidine / therapeutic use*
-
Organometallic Compounds / therapeutic use*
-
Pilot Projects
Substances
-
Anti-Bacterial Agents
-
Anti-Ulcer Agents
-
Organometallic Compounds
-
Clarithromycin
-
bismuth tripotassium dicitrate
-
Nizatidine